Cargando…
Rufinamide-Loaded Chitosan Nanoparticles in Xyloglucan-Based Thermoresponsive In Situ Gel for Direct Nose to Brain Delivery
In 2004, the US FDA approved Rufinamide, an anti-epileptic drug under the brand name Banzel(®). In 2015, Banzel(®) received approval for its use in pediatric patients (ages 1–4 years). Rufinamide shows low oral bioavailability due to a low dissolution rate resulting in less of the drug reaching the...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257053/ https://www.ncbi.nlm.nih.gov/pubmed/34234679 http://dx.doi.org/10.3389/fphar.2021.691936 |